What Have Large Semaglutide Trials Found?

What is the clearest answer on semaglutide for your health?

Trials with roughly 2,000 to more than 17,000 people found several clear health gains. Some included people with diabetes, and others studied weight, heart, or kidney health ^[7][8][9].

Semaglutide is a GLP-1 medicine that also helps lower blood sugar in type 2 diabetes. Among these three peptides, its human study record is far broader.

Tirzepatide caused more weight loss in one direct trial ^[6]. Strong proof doesn’t make semaglutide best on every measure that matters to you.

Semaglutide copies a gut hormone called GLP-1. After a meal, that hormone aids fullness and helps control blood sugar.

Doctors prescribe approved shots and tablets for set uses. The medicine can cause nausea and other harms, so your own doctor weighs both sides.

Why does semaglutide last so long?

Semaglutide has 31-amino-acid pieces joined like a small protein. Its make-up is about 94% like the natural gut hormone GLP-1.

Researchers number those pieces from one end. Changes to pieces 8, 26, and 34 slow the body from breaking the medicine down.

One change blocks DPP-4, an enzyme that normally breaks the medicine down. Another helps semaglutide cling to albumin, a common protein in blood.

Those changes keep the medicine in your blood for about one week. They explain why one shot can last that long.

Very little of the tablet passes from the stomach into the blood. An added helper lets some medicine pass through.

The tablet must be taken on an empty stomach with little water. Food and other medicine must wait for about half an hour.

How does semaglutide change appetite and sugar levels?

Semaglutide uses places on cells that normally respond to the gut hormone GLP-1. When sugar rises, the pancreas sends more insulin into the blood.

The medicine also lowers a hormone that pushes sugar upward. This two-part effect makes very low sugar less likely when semaglutide is used alone.

Food also leaves the stomach more slowly after a meal. The delay may soften a sugar rise, though it can bring nausea and a heavy feeling.

In the brain, GLP-1 increases fullness and reduces hunger ^[11]. Some people say the steady thought of food becomes quieter.

Heart and kidney trials found gains beyond weight and blood sugar ^[7][8]. Researchers are still working out how the medicine brings those gains.

What happened to people in the largest semaglutide trials?

Direct weight-loss trial, 2025. Researchers followed 751 adults with obesity and no diabetes in a 72-week trial. Average weight fell 20.2% with tirzepatide and 13.7% with semaglutide ^[6].

The paper’s chance test strongly supported the difference. On weight alone, tirzepatide did better in this trial.

Kidney trial, 2024. The study included 3,533 adults with long-term kidney disease and type 2 diabetes. Semaglutide cut kidney failure, major loss of kidney function, or kidney or heart death by 24% ^[7].

People received 1.0 milligram once a week or placebo, a look-alike treatment without semaglutide. The paper gave a 95% range to show how exact its estimate might be.

Heart trial, 2023. The 17,604 adults had excess weight and known heart disease, but no diabetes. Semaglutide cut heart death, non-fatal heart attack, or non-fatal stroke by 20% ^[8].

People received 2.4 milligrams or placebo. The paper gave a 95% range and found strong support beyond chance.

Weight trial, 2021. Researchers followed 1,961 adults with excess weight and no diabetes for 68 weeks. Weight fell 14.9% with 2.4 milligrams of semaglutide and 2.4% with placebo ^[9].

Safety review. Nausea affected roughly a third of patients with type 2 diabetes and often eased with time. Gallstones rose, while pancreas and thyroid cancers happened too seldom for reviewers to decide ^[10].

Mouse and rat work. The animals ate less and changed which foods they chose. They didn’t burn fewer calories, and this was not a human result ^[11].

Eye finding, 2016. A trial of 3,297 adults with type 2 diabetes found fewer major heart problems. That finding had a 95% range to show how exact it might be ^[12].

The same trial found more eye trouble caused by diabetes. That harm also had a 95% range, so the overall result wasn’t wholly good.

What do patients report, and what harms did studies find?

These patient accounts did not come from a controlled trial. Patient comment sites and one survey describe what some people felt while using semaglutide.

Many people said the constant thought of food grew quiet. Some noticed the change within the first one to two weeks after starting.

People also wrote about less desire for sugar, fried food, or alcohol. Others reported steady weight loss and better blood-sugar readings over several months.

Those comments don’t prove that the medicine caused each change. They also don’t set a dose or replace the checked study results below.

Patient reports of harm were not checked like a trial. Reviewers mentioned nausea more than any other complaint, often after an increase.

People also mentioned bad-smelling burps, constipation, loose stools, heartburn, tiredness, headaches, and hair loss. A report can warn you, but it doesn’t tell how common a harm is.

What trials and reviews found:

• Nausea leads the stomach and bowel complaints. It affected roughly a third of patients and was often mild or short-lived ^[10]. Some people still stopped treatment because they couldn’t bear it.
• The thyroid warning began with rodents. The warning also covers MEN-2, a rare illness passed through families ^[10]. A personal or family history of MEN-2 can bar use.
• Pancreatitis is a warning. This painful swelling of the pancreas was too rare to tie clearly to semaglutide ^[10]. Sudden strong belly pain needs prompt medical care.
• Gallstones rose in studies. Fast weight loss may explain much of that rise ^[10]. Gallbladder pain and blocked bile can still require hospital care.
• Diabetic eye trouble rose in one trial. The risk appeared highest when people with old eye disease had a quick fall in blood sugar ^[12][10]. An eye doctor may need to watch such a change.
• Other concerns need a doctor’s review. They include muscle loss, weight return after stopping, pregnancy, and tablet use ^[10]. The tablet needs an empty stomach, little water, and about half an hour before food or other medicine.

How does semaglutide compare with the other two?

Among these three compounds, semaglutide has the deepest human record. Tens of thousands joined trials on diabetes, obesity, heart disease, and kidney disease.

MOTS-c relies mostly on mice, cells, and one human blood study. Tesamorelin has one well-tested use in a narrow group.

A newer drug still produced a larger weight change in one direct trial ^[6]. Strong proof about many uses does not make one drug best at every task.

The comparison page sorts the studies by the people who took part. That helps you separate a broad record from a single good result.